BBK Worldwide was recently chosen by the Diabetes Patient Advocacy Coalition (DPAC) to create a new corporate identity and brand to reflect the new organizations commitment to focus lawmakers’ attention on diabetes patients and their needs.
Topics: Branding and Advertising
BBK Worldwide is excited to be leading two Innovation Theater panels at this year’s DIA event, taking place June 14-18 in Washington, DC. BBK Co-Founder Bonnie A. Brescia will lead our first discussion on Monday, June 15 from 4:15-4:45 p.m. with Claire Meunier, VP, Research Engagement with The Michael J. Fox Foundation and Christel Aprigliano, CEO of the Diabetes Collective.
Topics: Patient Centricity
In earlier posts we have explored how mHealth can increase both patient engagement and site engagement. Today’s blog comes from Jason Rightmyer, Director of Research Informatics with the Institute of Aging Research (a Harvard Medical School Affiliate) who explores how mobile health technology is attributing to physician engagement. Thanks for contributing!
During our recent webinar, “mHealth + Patient Engagement: A New Connected Health Model”, our panelists, Dan Bender (Empatica), Larry Suarez (Oracle) and Jaime Cohen (BBK Worldwide) received many thought-provoking questions throughout the hour. While we were able to answer a few on the spot, there were many that we didn’t have time to address. Below, Jaime takes a turn answering your burning questions.
BBK Worldwide is once again looking forward to attending Drug Information Association 2015 (DIA), which this year will take place from June 15 - 18 at the Walter E. Washington Convention Center in DC. We always love attending this annual event – the industry’s largest, which attracts more than 7,000 attendees each year. DIA provides a global, unbiased platform to raise the level of discussion to facilitate innovation that will change the future of healthcare.
While the push for sponsors to go global with clinical studies is old news, the industry has been working hard to develop and invest in ways to choose the right sites and countries. Ultimately, site selection matters because investigator sites are the only place where study volunteers can participate in clinical research. Enrollment is the end game – further drug development, regulatory submissions and marketing are contingent on having this data.
Again this year I was privileged to participate in the Women’s Clinical Leadership Dinner, hosted by the Partnerships in Clinical Trials Conference. With so many women in life sciences leadership roles here in Boston, it was fitting to gather right in our own backyard. (And for those of you who missed the dinner, look for it again next spring at Partnerships in Boston.)
Just about everyone carries a mobile device these days. Whether you’re in line for your morning coffee or on the treadmill at the gym, most people have their phones close at hand. So how can we utilize today’s connected mHealth model to better tap into clinical trial patients through means they are already using, such as their phones?
Not that long ago, the healthcare sector was considered an IT laggard. Today, cloud-based infrastructures and solutions are the norm.
During the first 25 years of the Orphan Drug Act (passed in 1983), only 326 new drugs were approved by the FDA and brought to market for all rare disease patients combined. Prior to the Orphan Drug Act, fewer than 10 treatments had been developed by industry for rare diseases. This is progress however; there is a lot of work to be done.